European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics – Update 2019
Claus Garbe(University Children's Hospital Tübingen), Alexander M.M. Eggermont(Institut Gustave Roussy), Véronique Bataille(King's College London), Ricardo Vieira(Hospitais da Universidade de Coimbra), D. Moreno‐Ramírez(Hospital Universitario Virgen Macarena), Célèste Lebbé(Inserm), Petr Arenberger(Charles University), Philippe Saïag(Université de Versailles Saint-Quentin-en-Yvelines), Roland Kaufmann(Jet Company (Czechia)), Axel Hauschild(Kiel University), Josep Malvehy(Instituto de Salud Carlos III), Mark R. Middleton(University of Oxford), Maria Concetta Fargnoli(University of L'Aquila), Teresa Amaral(University of Tübingen), Aimilios Lallas(Aristotle University of Thessaloniki), Lars Bastholt(Odense University Hospital), V. del Mármol(Université Libre de Bruxelles), Iris Zalaudek(University of Trieste), Alexander J. Stratigos(National and Kapodistrian University of Athens), Ketty Peris(Università Cattolica del Sacro Cuore), Christoph Höller(Medical University of Vienna), Giovanni Pellacani(Sapienza University of Rome), Jean-Jacques Grob(Aix-Marseille Université), Brigitte Dréno(Inserm)
Cited by 191
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.8k
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
|New England Journal of Medicine|2016|1.3k
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
|Journal of Clinical Oncology|2000|1.3k